Ernexa Therapeutics Inc. (ERNAW) Free cash flow 2016–2025
Ernexa Therapeutics Inc. (ERNAW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$7.1MFY2025 · since FY2016: -$404,000 → -$7.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.1M | +56.5% |
| FY2024 | -$16.2M | +20.7% |
| FY2023 | -$20.4M | +4.0% |
| FY2022 | -$21.3M | +10.0% |
| FY2021 | -$23.6M | -190.4% |
| FY2020 | -$8.1M | -411.2% |
| FY2019 | $2.6M | +264.9% |
| FY2018 | $717,000 | +500.6% |
| FY2017 | -$179,000 | +55.7% |
| FY2016 | -$404,000 | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice